Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Orion Oyj Director's Dealing 2024

Mar 4, 2024

3232_dirs_2024-03-04_8b26eb78-dde0-4a59-a820-99a44da28ced.html

Director's Dealing

Open in viewer

Opens in your device viewer

Disclosure 443303

Orion - Managers' transactions

Orion Corporation: Managers' transactions - Hao Pan

ORION CORPORATION

MANAGERS’ TRANSACTIONS

4 MARCH 2024 at 13.00 EET

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Hao Pan

Position: Other senior manager

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 54284/5/4

____________________________________________

Transaction date: 2024-03-01

Outside a trading venue

Instrument type: SHARE

ISIN: FI0009014377

Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details

(1): Volume: 4247 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 4247 Volume weighted average price: 0 EUR

Orion Corporation

Liisa Hurme



President and CEO
Olli Huotari



SVP, Corporate Functions

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.